Clinical trial SCARLET
Somatostatin receptors imaging in relapsing and refractory multiple myeloma patients (SCARLET)
| Organ | Myeloma |
|---|---|
| Trial status | Trial open for recruitment |
| Trial type |
Interventional without experimental drug
|
| Phase | Trial phase 2 |
| Academic trial | Oui |
| Sponsor | Bordet |
| BECT Identifier | B079202043046 |
| Inclusion criteria | * Confirmed diagnosis of multiple myeloma according to the Salmon and Durie criteria* Has received at least three lines of treatment, exposed and refractory (or non-eligible) to the 5 major drugs (lenalidomide, pomalidomid, bortezomib, carfilzomib, dara |
| Last update |